EGFR and non-small cell lung carcinoma: Preliminary results from a phase II study, evaluating the combination of capmatinib and gefitinib in EGFR mutated NSCLC patients who progressed on EGFR TKI, reported an ORR of 19% in patients with MET IHC3+ or MET IHC≥2+ and MET GCN≥5 and raised to 30% in the subgroup of patients with MET GCN≥6 [37].